Medicare AdvantageAugust 20, 2024
Drug and biologic
Effective December 1, 2024, BMA is enhancing its claim edits system to ensure claims billed with pharmaceutical drug procedure codes are reported with the appropriate FDA-approved indicators for on- and off-label use.
These enhanced claim edits provide an opportunity for BMA to evaluate submitted claims for drug quality, safety, and effectiveness. The enhancement is to have the claims deny if not billed with FDA indicator for on/off label use.
If you believe a claim reimbursement decision should be reviewed, please follow the normal claims dispute process outlined in the provider manual and include medical records that clarify whether the indication was approved through the governing agencies. You will need to submit only the portion(s) of the medical record that is relevant to the drug provided.
If you have questions about this notification, contact your contract manager or provider relationship management account representative.
Blue Medicare Advantage is the trade name of Group Retiree Health Solutions, Inc., an independent licensee of the Blue Cross Blue Shield Association.
PAIBC-CR-063028-24-CPN62565
To view this article online:
Visit https://providernews.anthem.com/pennsylvania/articles/drug-and-biologic-21548
Or scan this QR code with your phone